Genetic Technologies (GENE +0.8%) announces that ImmunAid Limited, in which the company holds a 45% direct equity interest and is currently the largest shareholder, has just been granted its first patent by the USPTO. The company has been working since 2001 to develop an entirely new treatment strategy for patients with life-threatening diseases, whereby the unique immune cycle of each individual patient is monitored on an individual basis, in order to determine the precise optimal time to deliver treatment. The company received its first round of funding in 2011.
Genetic Technologies (GENE +0.8%) announces that ImmunAid Limited, in which the company holds a...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs